PharmaSGP Holding SE | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
PharmaSGP Holding SE

BRIEF

published on 06/10/2025 at 08:47, 5 months 24 days ago

PharmaSGP Announces Delisting Agreement with FUTRUE GmbH

Stock Exchange Tender Offer Delisting PharmaSGP Futrue GmbH
PRESS RELEASE

published on 06/10/2025 at 08:42, 5 months 24 days ago

EQS-Adhoc: PharmaSGP Holding SE: Conclusion of a delisting agreement and announcement of a delisting tender offer by FUTRUE GmbH
PharmaSGP Holding SE announces a delisting tender offer by FUTRUE GmbH, exceeding the share price. Delisting is to reduce regulatory burden and costs

Cost Reduction Tender Offer Delisting PharmaSGP Regulatory Burden
BRIEF

published on 06/10/2025 at 08:40, 5 months 24 days ago

Futrue GmbH Launches Delisting Offer for PharmaSGP Holding SE

Frankfurt Stock Exchange Share Acquisition Delisting Offer PharmaSGP Futrue GmbH
PRESS RELEASE

published on 06/10/2025 at 08:35, 5 months 24 days ago

EQS-WpÜG: Tender Offer / Target company: Pharma SGP Holding SE; Bidder: Futrue GmbH
FUTRUE GmbH announces public delisting tender offer to acquire remaining shares of PharmaSGP Holding SE. Offer price is EUR 28.00 per PharmaSGP Share. Bidder intends to squeeze out minority shareholders post-settlement

Delisting Tender Offer Squeeze-out Minority Shareholders PharmaSGP Holding SE Futrue GmbH
BRIEF

published on 05/15/2025 at 07:35, 6 months 20 days ago

PharmaSGP Begins 2025 With Revenue Growth

Growth Strategy Financial Performance PharmaSGP OTC Pharmaceuticals 2025 Revenue
PRESS RELEASE

published on 05/15/2025 at 07:30, 6 months 20 days ago

PharmaSGP continues its growth course in 2025
PharmaSGP Holding SE achieves 10.8% revenue growth in Q1 2025, with adjusted EBITDA rising to €9.2 million. Company forecasts 2025 revenue increase and maintains strong financial basis

Adjusted EBITDA Revenue Growth PharmaSGP 2025 Forecast Financial Basis
BRIEF

published on 04/15/2025 at 07:35, 7 months 19 days ago

PharmaSGP Reports Revenue and EBITDA Growth in 2024

Revenue Growth Organic Growth EBITDA Increase 2025 Forecast PharmaSGP Strategy
PRESS RELEASE

published on 04/15/2025 at 07:30, 7 months 19 days ago

PharmaSGP with significant increase in revenues and EBITDA in 2024
PharmaSGP Holding SE achieved significant revenue and EBITDA growth in 2024. Revenues increased by 17.5% to €118.8 million, with adjusted EBITDA reaching €37.2 million. Management foresees further growth in 2025 amidst global uncertainty

EBITDA Revenue Growth 2024 Financial Year PharmaSGP Holding SE Organic Expansion
BRIEF

published on 11/14/2024 at 07:35, 1 year ago

PharmaSGP Sees Strong Revenue Growth in 9M 2024, Raises Full-Year Forecast

Revenue Growth Market Strategy 2024 Forecast PharmaSGP OTC Pharmaceuticals
PRESS RELEASE

published on 11/14/2024 at 07:30, 1 year ago

PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised
PharmaSGP Holding SE reports strong revenue growth in 9 months of 2024, with preliminary figures showing a 17.0% increase compared to the same period last year. FY 2024 revenue forecast raised

Financial Results Revenue Growth Pharmaceuticals Forecast PharmaSGP

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 32 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 37 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 7 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 2 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 7 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 3 hours 36 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 16 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 41 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 52 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 56 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 13 hours 7 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 22 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 23 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE